Effect of gastric pH on the pharmacokinetics of a BCS Class II compound in dogs: Utilization of an artificial stomach and duodenum dissolution model and GastroPlus,™ simulations to predict absorption

Journal of Pharmaceutical Sciences

Volumn 100, Issue 11, 2011, Pages 4756-4765

  Bhattachar, Shobha N ^a   Perkins, Everett J ^a   Tan, Jeffrey S ^a   Burns, Lee J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Absorption; Dissolution; In silico modeling; in vitro in vivo correlations (IVIVC); Pharmacokinetics; Solubility

Indexed keywords

LY 2157299; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ARTIFICIAL ORGAN; COMPUTER MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DUODENUM; FEMALE; FIRST PASS EFFECT; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; STOMACH; STOMACH ABSORPTION; STOMACH PH;

EID: 80053221530     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22669     Document Type: Article

References (17)

1. Martinez MN, Amidon GL. 2002. A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals. J Clin Pharmacol 42:620-643.
2. Charman WN, Porter CJ, Mithani S, Dressman JB. 1997. Physiochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J Pharm Sci 86:269-282.
3. Lui CY, Amidon GL, Berardi RR, Fleisher D, Youngberg C, Dressman JB. 1986. Comparison of gastrointestinal pH in dogs and humans: Implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci 75:271-274.
4. Tibbitts J. 2003. Issues related to the use of canines in toxicologic pathology-Issues with pharmacokinetics and metabolism. Toxicol Pathol 31 Suppl:17-24.
5. Akimoto M, Nagahata N, Furuya A, Fukushima K, Higuchi S, Suwa T. 2000. Gastric pH profiles of beagle dogs and their use as an alternative to human testing. Eur J Pharm Biopharm 49:99-102.
6. Yingling JM, Blanchard KL, Sawyer JS. 2004. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov, 3(12):1011-1022.
7. Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, Troconiz IF. 2008. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 44:142-150.
8. Calvo-Aller E, Baselga J, Glatt S, Cleverly A, Lahn M, Arteaga CL, Rothernberg ML, Carducci M. 2008. First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299. America Society of Clinical Oncology 2008 Annual Meeting May 20 suppl; abstr 14554.
9. Kostewicz ES, Brauns U, Becker R, Dressman JB. 2002. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm Res 19:345-349.
10. Okumu A, DiMaso M, Lobenberg R. 2008. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. Pharm Res 25:2778-2785.
11. Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, Yamashita S. 2006. Oral absorption of poorly water-soluble drugs: Computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res 23:1144-1156.
12. Gu CH, Rao D, Gandhi RB, Hilden J, Raghavan K. 2005. Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility. J Pharm Sci 94:199-208.
13. Takano R, Furumoto K, Shiraki K, Takata N, Hayashi Y, Aso Y, Yamashita S. 2008. Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm Res 25:2334-2344.
14. Zhou R, Moench P, Heran C, Lu X, Mathias N, Faria TN, Wall DA, Hussain MA, Smith RL, Sun D. 2005. pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: Development of a canine model. Pharm Res 22:188-192.
15. Smeets-Peeters M, Watson T, Minekus M, Havenaar R. 1998. A review of the physiology of the canine digestive tract related to the development of in vitro systems. Nutr Res Rev 11:45-69.
16. Carino SR, Sperry DC, Hawley M. 2006. Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model. J Pharm Sci 95:116-125.
17. Stoline MR. 1981. The status of multiple comparisons: Simultaneous estimation of all pairwise comparisons in one-way ANOVA designs. Am Stat 35:134-141.